NextPoint Therapeutics, Inc.

General Information

Company Name

Founded Year

2020

Location (Offices)

Founders / Decision Makers

Number of Employees

Industries

Biotechnology, Health Care, Health and Wellness +1

Funding Stage

Series B

Social Media

NextPoint Therapeutics, Inc. - Company Profile

NextPoint Therapeutics, Inc. is a biotechnology startup with the slogan "Expanding the potential of immunotherapy." Founded in 2020, the company is at the forefront of immuno-oncology, focusing on the novel HHLA2 checkpoint axis.

NextPoint is distinguished by its integration of foundational science with a defined clinical biomarker strategy, which aims to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. Additionally, the company is advancing therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

The most recent milestone for NextPoint was a $42.50M Series B investment on 14 February 2024. The investors in this funding round included MPM Capital, Invus, 60 Degree Capital, Arkin Holdings, Binney Street Capital, Catalio Capital Management, Leaps by Bayer, Sanofi Ventures, Gordon Freeman, WTT Investment. With a proven team of drug developers and renowned scientific founders, NextPoint is poised to launch a new era of precision immuno-oncology and beyond.

Taxonomy: Immunotherapy, Immuno-oncology, HHLA2 checkpoint axis, Monotherapies, Therapeutic modalities, Clinical-stage biotechnology, Cancer treatment, Precision medicine, Tumor targeting, Innovative approach, Clinical biomarker strategy, Adaptive immune system, Innate immune system, Drug development, Therapeutics